GLP-1s and Sleep Apnea

The short answer

Yes — Zepbound (tirzepatide) became the first medication ever FDA-approved for obstructive sleep apnea (OSA) in December 2024, specifically for adults with OSA and obesity. The approval is based on the SURMOUNT-OSA trial, which showed dramatic reductions in apnea–hypopnea index (AHI) when tirzepatide was added to standard care. It does not replace CPAP for moderate-to-severe OSA, but for many patients with obesity-driven OSA it offers the first realistic path to needing less of it — or, eventually, none.

What the research shows

SURMOUNT-OSA was a two-part phase 3 trial enrolling 469 adults with moderate-to-severe OSA and obesity. One arm enrolled patients not using CPAP; the other enrolled patients on stable CPAP therapy. Both received either tirzepatide (titrated to maximum tolerated, up to 15 mg weekly) or placebo for 52 weeks. The primary endpoint was change in AHI — the number of breathing pauses per hour of sleep.

The results were striking. Mean baseline AHI was around 50 events per hour (severe OSA). Tirzepatide reduced AHI by roughly 25–30 events per hour, compared to about 5–6 events per hour with placebo. That is the largest AHI reduction any pharmacotherapy has ever shown in OSA. In percentage terms, roughly half of tirzepatide-treated patients in the non-CPAP arm reached an AHI below 5 or had at least a 50% reduction with AHI under 15 — the standard remission threshold.

Weight loss was the obvious mediator. Tirzepatide reduced body weight by roughly 18–20% in this population, consistent with SURMOUNT-1. Other improvements followed: oxygen saturation during sleep improved, systolic blood pressure dropped about 7 mmHg, and patient-reported sleep disturbance and sleepiness scores improved. The FDA approval in December 2024 made Zepbound the first OSA medication, period.

What the trial did not show is that GLP-1 therapy replaces CPAP. The CPAP-using arm continued to use CPAP throughout, and they also benefited — better sleep quality and blood pressure on top of CPAP. The take-home is that GLP-1 therapy treats the underlying cause (obesity-driven upper airway collapse) while CPAP treats the immediate symptom (airway closure during sleep). The two are complementary in the short term, with the possibility of de-escalating CPAP over time as weight comes down.

How it tends to work in practice

Patients tend to notice subjective sleep improvements before any objective AHI change registers — less daytime sleepiness, fewer morning headaches, partners reporting less snoring. This often shows up in months 2–4, well before a repeat sleep study would be ordered. The objective AHI drop tracks the weight loss curve closely; meaningful reductions typically appear around 10–15% body-weight loss, with the largest gains as patients reach 15–20%.

Sleep specialists generally recommend continuing CPAP throughout the weight-loss phase. The reasoning is practical: AHI fluctuates night-to-night, daytime function and cardiovascular protection depend on stable nightly treatment, and a missed night of CPAP at AHI 30 still raises cardiac event risk. The recommended approach is a repeat in-lab or home sleep study at 6–12 months, with CPAP pressure re-titration or discontinuation decided from that data.

The patients who respond most dramatically tend to be those with positional or weight-dependent OSA — fat distribution around the neck and tongue base is the dominant mechanism, and weight loss directly addresses it. Patients with strong craniofacial contributions (small jaw, retrognathia) may see less complete AHI normalization, because the bony airway geometry doesn't change with weight.

Common questions

Keep exploring

Browse all GLP-1 guides.